Patients with metastatic breast cancer are needed for a study to research an investigational drug combination involving an immunotherapy and a cellular therapy.

IRB/UVA Tracking #
19406
Principal Investigator
Patrick M Dillon
Contact
Jungeun Kim
Contact Email
Contact Phone
434.982.0074
Official Trial Title
A Phase I/II Study of Anti-CD3 x Anti-HER2/neu (Her2Bi) Armed Activated T Cells (ATC) and Pembrolizumab combination therapy in Women with metastatic breast cancer.
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have metastatic breast cancer. The purpose of this study to evaluate an experimental drug combination including an immunotherapy drug (pembrolizumab) and a cellular therapy drug (HER2-BATs) in patients with metastatic breast cancer. The drug dose, safety, and the effects of the cellular therapy drug alone and in combination with the immunotherapy drug will be evaluated for this study.

Participation is approximately 17 study visits over 8 months. This includes a screening period, leukapheresis procedure, 7-8 weeks of study drug treatment, and 4 additional follow-up clinic visits. Study specific tests that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03272334

Compensation

No Compensation; Reimbursement: You may stay in hotel accommodations arranged by the study team if you live over 40 minutes away.